We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Lateral Flow Immunoassay Evaluated for Respiratory Samples

By LabMedica International staff writers
Posted on 08 Jan 2013
Rapid point-of-care pathogen detection remains a challenge, especially for Staphylococcus aureus detection in respiratory samples. More...


A rapid S. aureus–specific lateral flow immunochromatography (LFI) test has been developed using a specific monoclonal antibody to the S. aureus cell-wall peptidoglycan.

Scientists at King's College London (UK) used a LFI strip and modified the antigen target and capture/detection antibody to achieve greater sensitivity and specificity. They used an affinity-purified mouse monoclonal anti-S. aureus antibody that was raised specifically against S. aureus cell-wall peptidoglycan and conjugated with gold colloid. They used samples from six volunteers with severe asthma as well as spiked sputum and bronchial lavage specimens.

The LFI test was shown to be specific for S. aureus with no signal development for other Staphylococcal species or common respiratory pathogens. Evaluation of S. aureus isolates spiked into induced sputum and bronchoalveolar lavage samples derived from severe asthmatic patients showed a detection limit of 106 colony forming units (CFU)/mL for the LFI. The LFI test strips positively detected methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA). The test was also shown to successfully detect S. aureus in one sample independently determined to be S. aureus positive by quantitative polymerase chain reaction.

The authors concluded that that an LFI detection limit of equal to or greater than 106 CFU/mL may be sufficiently sensitive to screen for preliminary information in a number of applications, but LFI tests with lower detection limits of less than 104 CFU/mL would be more clinically relevant. Further studies are currently ongoing to lower the detection limits of the LFI test and evaluate the robustness of the assay for a number of different applications. The ability of the LFI test to rapidly detect S. aureus in clinical respiratory samples suggests that it might be a useful platform for further development of point-of-care diagnostic applications. The study was published in the January 2013 edition of the journal Diagnostic Microbiology & Infectious Diseases.

Related Links:
King's College London



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.